Temozolomide Market, By Indication (Newly Diagnosed Glioblastoma Multiforme and Refractory Anaplastic Astrocytoma), By Type (Generic and Branded), By Route of Administration (Oral (Capsules) and Intravenous (Injection)), By Strength (5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg), By Age Group (Adults, Pediatric, and Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Specialty Clinics (Oncology and Neuro-oncology centers), and Others (Research and Academic Institutes, etc.)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Select a License Type that Suits your Business Needs
US$ 2,000
Two thousand dollars
Single User License
( Full Report )
US$ 4,500
US$ 3,000
Three thousand dollars
Frequently purchased
Multi User License
( Full Report )
US$ 7,000
US$ 5,000
Five thousand dollars
Corporate User License
( Full Report )
US$ 10,000
US$ 6000
Six thousand dollars
Client Testimonials
Client Testimonials
Our Clients
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

860519526
9001:2015
27001:2022